EVLO - Why Is Psoriasis Company Evelo Biosciences Stock Plunging Today? | Benzinga
Evelo Biosciences Inc (NASDAQ: EVLO) released top-line results from its Phase 2 clinical study with EDP2939 in moderate psoriasis.
EDP2939 is a next-generation product candidate based on previously reported Phase 2 data in psoriasis with the company's first-generation product, EDP1815.
The study's primary endpoint, the difference in the proportion of patients who achieved an outcome of a 50% improvement from baseline in Psoriasis Area and Severity Index (PASI) ...